Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of age-related dementia. Currently available pharmacologic therapies, including acetylcholinesterase (AChE) inhibitors and N-m...
Alzheimer's disease is a neurodegenerative disorder manifested by cognitive and memory deterioration, impairment of language, and other activities of daily life. Two major pathological hallmarks are characteristics of Al...
Alzheimer's disease (AD) is a neurodegenerative disease characterized by the progressive formation of insoluble amyloid plaque and fibrillary tangles. Plaques are extracellular constructs consisting primarily of A beta(4...
This review discusses the involvement of structure and modeling in the design of beta-secretase (BACE-1) and gamma-secretase inhibitors as putative Alzheimer's Disease therapeutics. The early and broad availability of st...
Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of A beta peptide, neurofibrillary tangles (NIFTs) made up of hyperphosphorylated tau, and a deficit of cholinergic neuron...
Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid beta peptide (A beta). Recent clinical trial results question...
Among the potential therapeutic targets for the development of cognitive enhancers for AD and schizophrenia, the 5-HT6 receptor is of especial interest based on its localization, pharmacology, and recent behavioral data ...